MA39926B1 - Dérivés de dihétérocycle liés à cycloalkyle - Google Patents

Dérivés de dihétérocycle liés à cycloalkyle

Info

Publication number
MA39926B1
MA39926B1 MA39926A MA39926A MA39926B1 MA 39926 B1 MA39926 B1 MA 39926B1 MA 39926 A MA39926 A MA 39926A MA 39926 A MA39926 A MA 39926A MA 39926 B1 MA39926 B1 MA 39926B1
Authority
MA
Morocco
Prior art keywords
cycloalkyl
compounds
derivatives
linked
mammals
Prior art date
Application number
MA39926A
Other languages
English (en)
Inventor
Pei-Pei Kung
Aaron Craig Burns
Michael Raymond Collins
Samantha Elizabeth Greasley
Robert Louis Hoffman
Qinhua Huang
Robert Steven Kania
Maria Angelica Linton
Lakshmi Sourirajan Narasimhan
Paul Francis Richardson
Daniel Tyler Richter
Graham Smith
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA39926B1 publication Critical patent/MA39926B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des composés de formule (i) ou des sels pharmaceutiquement acceptables de ceux-ci. Dans ladite formule, a, l, d, r1-r15, w, x, y et z sont tels que définis dans la description. Ces nouveaux dérivés de de dihétérocycle liés à cycloalkyle sont utiles dans le traitement d'une croissance cellulaire anormale, telle que le cancer, chez les mammifères. L'invention concerne également des compositions pharmaceutiques contenant ces composés, et des méthodes d'utilisation de ces composés et compositions dans le traitement d'une croissance cellulaire anormale chez les mammifères.
MA39926A 2014-04-30 2015-04-17 Dérivés de dihétérocycle liés à cycloalkyle MA39926B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461986876P 2014-04-30 2014-04-30
EP15726701.4A EP3137460B1 (fr) 2014-04-30 2015-04-17 Dérivés de dihétérocycle liés à cycloalkyle
PCT/IB2015/052833 WO2015166373A1 (fr) 2014-04-30 2015-04-17 Dérivés de dihétérocycle liés à cycloalkyle

Publications (1)

Publication Number Publication Date
MA39926B1 true MA39926B1 (fr) 2019-12-31

Family

ID=53276932

Family Applications (2)

Application Number Title Priority Date Filing Date
MA39926A MA39926B1 (fr) 2014-04-30 2015-04-17 Dérivés de dihétérocycle liés à cycloalkyle
MA049708A MA49708A (fr) 2014-04-30 2015-04-17 Dérivés de dihétérocycle liés à cycloalkyle

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA049708A MA49708A (fr) 2014-04-30 2015-04-17 Dérivés de dihétérocycle liés à cycloalkyle

Country Status (41)

Country Link
US (4) US20170050958A1 (fr)
EP (2) EP3556757A1 (fr)
JP (2) JP6574203B2 (fr)
KR (1) KR20160149256A (fr)
CN (1) CN106232598B (fr)
AP (1) AP2016009530A0 (fr)
AU (1) AU2015254943B2 (fr)
BR (1) BR112016024513A2 (fr)
CA (1) CA2947130C (fr)
CL (1) CL2016002532A1 (fr)
CR (1) CR20160497A (fr)
CU (1) CU24420B1 (fr)
CY (1) CY1122439T1 (fr)
DK (1) DK3137460T3 (fr)
DO (1) DOP2016000293A (fr)
EA (1) EA033919B1 (fr)
EC (1) ECSP16083017A (fr)
ES (1) ES2759434T3 (fr)
GE (1) GEP20186879B (fr)
GT (1) GT201600232A (fr)
HK (1) HK1232212A1 (fr)
HR (1) HRP20192056T1 (fr)
HU (1) HUE046518T2 (fr)
IL (1) IL248629B (fr)
LT (1) LT3137460T (fr)
MA (2) MA39926B1 (fr)
MD (1) MD20160111A2 (fr)
MX (1) MX2016014143A (fr)
NI (1) NI201600163A (fr)
NZ (1) NZ725496A (fr)
PE (1) PE20161436A1 (fr)
PH (1) PH12016501997A1 (fr)
PL (1) PL3137460T3 (fr)
PT (1) PT3137460T (fr)
RS (1) RS59617B1 (fr)
SG (1) SG11201608634RA (fr)
SI (1) SI3137460T1 (fr)
SV (1) SV2016005310A (fr)
TN (1) TN2016000459A1 (fr)
UA (1) UA117861C2 (fr)
WO (1) WO2015166373A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106029659B (zh) * 2014-01-06 2020-08-11 理森制药股份公司 谷氨酰胺酶抑制剂
BR112016024513A2 (pt) 2014-04-30 2017-08-15 Pfizer derivados de di-heterociclo ligados à cicloalquila
CN107474024B (zh) * 2016-06-08 2022-12-13 北京赛林泰医药技术有限公司 一种谷氨酰酶抑制剂及其组合物和用途
CN110746416A (zh) * 2019-09-05 2020-02-04 中国药科大学 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途
CN116023375A (zh) * 2021-10-25 2023-04-28 成都苑东生物制药股份有限公司 一种杂环类衍生物、其制备方法及用途

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
DK0584222T3 (da) 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US5702637A (en) 1995-04-19 1997-12-30 Minnesota Mining And Manufacturing Company Liquid crystal compounds having a chiral fluorinated terminal portion
DK0821671T3 (da) 1995-04-20 2001-04-23 Pfizer Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
JPH09104838A (ja) 1995-10-09 1997-04-22 Mitsui Toatsu Chem Inc 水性塗料用樹脂組成物
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69624081T2 (de) 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix-metalloprotease Inhibitoren
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
EP0912572B1 (fr) 1996-07-13 2003-01-15 Glaxo Group Limited Composes heteroaromatiques bicycliques en tant qu'inhibiteurs de la proteine tyrosine kinase
ID19609A (id) 1996-07-13 1998-07-23 Glaxo Group Ltd Senyawa-senyawa heterosiklik
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
YU1899A (sh) 1996-07-18 2000-03-21 Pfizer Inc. Inhibitori matričnih metaloproteaza na bazi fosfinata
EA199900139A1 (ru) 1996-08-23 1999-08-26 Пфайзер, Инк. Производные арилсульфониламиногидроксамовой кислоты
PT950059E (pt) 1997-01-06 2004-10-29 Pfizer Derivados de sulfona ciclicos
AU721748B2 (en) 1997-02-03 2000-07-13 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
AU5493598A (en) 1997-02-07 1998-08-26 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
EA002546B1 (ru) 1997-02-11 2002-06-27 Пфайзер Инк. Производные арилсульфонилгидроксамовой кислоты
ES2239393T3 (es) 1997-05-07 2005-09-16 Sugen, Inc. Derivados de 2-indolinona utilizados como moduladores de la actividad de la proteina-quinasa.
AU734009B2 (en) 1997-05-30 2001-05-31 Merck & Co., Inc. Novel angiogenesis inhibitors
ES2289791T3 (es) 1997-08-22 2008-02-01 Astrazeneca Ab Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
CA2309690A1 (fr) 1997-11-11 1999-05-20 Pfizer Products Inc. Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
CO5031249A1 (es) 1998-05-29 2001-04-27 Sugen Inc Pirrol substituido-2-indolinonas inhibidoras de proteinci-nasas
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
DK1292591T3 (da) 2000-06-22 2005-05-30 Pfizer Prod Inc Bicykliske derivater til behandling af abnorm cellevækst
US6451828B1 (en) 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
DE10109807A1 (de) 2001-03-01 2002-09-05 Wella Ag Verbrückte Diaminopyrazole und diese Verbindungen enthaltende Färbemittel
US7029729B2 (en) 2003-02-24 2006-04-18 3M Innovative Properties Company Cholesteric liquid crystal additives
ES2279446T3 (es) 2003-08-15 2007-08-16 MERCK & CO., INC. Antagonistas nmda/nr2b de 4-cicloalquilaminopirazolo pirimidina.
US20080015202A1 (en) 2004-09-09 2008-01-17 Astellas Pharma Inc. Thiazole Derivatives Having Vap-1 Inhibitory Activity
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
AU2012340866B2 (en) * 2011-11-21 2017-03-16 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
US9672526B2 (en) 2012-03-13 2017-06-06 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
US9115120B2 (en) 2012-08-24 2015-08-25 Board Of Regents, The University Of Texas Systems Heterocyclic modulators of HIF activity for treatment of disease
CA2891667A1 (fr) 2012-11-16 2014-05-22 Calithera Biosciences Inc. Inhibiteurs de glutaminase heterocycliques
JP6333280B2 (ja) 2012-11-21 2018-05-30 アジオス ファーマシューティカルズ， インコーポレイテッド グルタミナーゼ阻害剤およびその使用方法
US9029531B2 (en) * 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014079011A1 (fr) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Composés hétérocycliques pour inhiber la glutaminase et procédés d'utilisation de ceux-ci
JP6285950B2 (ja) 2012-12-03 2018-02-28 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼの複素環式阻害剤を用いるがんの処置
US9868705B2 (en) * 2013-09-27 2018-01-16 The Board Of Trustees Of The University Of Illinois Tetra-aryl cyclobutane inhibitors of androgen receptor action for the treatment of hormone refractory cancer
WO2015061432A1 (fr) 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Traitement d'infections virales avec des inhibiteurs de glutaminase
CN106029659B (zh) 2014-01-06 2020-08-11 理森制药股份公司 谷氨酰胺酶抑制剂
US20150258082A1 (en) 2014-03-14 2015-09-17 Francesco Parlati Combination therapy with glutaminase inhibitors
EA201691896A1 (ru) 2014-03-21 2017-01-30 Аджиос Фармасьютикалз, Инк. Соединения и способы их применения
BR112016024513A2 (pt) 2014-04-30 2017-08-15 Pfizer derivados de di-heterociclo ligados à cicloalquila
MX2016016364A (es) 2014-06-13 2017-04-06 Calithera Biosciences Inc Terapia de combinacion con inhibidores de glutaminasa.
WO2016014890A1 (fr) 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Traitement du myélome multiple avec des inhibiteurs hétérocycliques de la glutaminase
MX2017012408A (es) 2015-03-30 2018-04-26 Calithera Biosciences Inc Metodos para administrar inhibidores de glutaminasa.
MX2017012824A (es) 2015-04-06 2018-05-15 Calithera Biosciences Inc Tratamiento de cáncer de pulmón con inhibidores de glutaminasa.
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys
JP6943759B2 (ja) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 シフト装置

Also Published As

Publication number Publication date
EA033919B1 (ru) 2019-12-10
HK1232212A1 (zh) 2018-01-05
GEP20186879B (en) 2018-07-10
EP3137460B1 (fr) 2019-10-23
HUE046518T2 (hu) 2020-03-30
IL248629B (en) 2019-07-31
CU24420B1 (es) 2019-06-04
WO2015166373A1 (fr) 2015-11-05
JP2017514818A (ja) 2017-06-08
SI3137460T1 (sl) 2019-12-31
MA49708A (fr) 2020-06-03
CY1122439T1 (el) 2020-11-25
ECSP16083017A (es) 2017-03-31
IL248629A0 (en) 2017-01-31
MD20160111A2 (ro) 2017-06-30
PH12016501997B1 (en) 2017-01-09
RS59617B1 (sr) 2020-01-31
HRP20192056T1 (hr) 2020-02-21
PH12016501997A1 (en) 2017-01-09
LT3137460T (lt) 2019-12-10
US20190270737A1 (en) 2019-09-05
EP3556757A1 (fr) 2019-10-23
US20170050958A1 (en) 2017-02-23
UA117861C2 (uk) 2018-10-10
ES2759434T3 (es) 2020-05-11
PT3137460T (pt) 2019-12-30
CU20160157A7 (es) 2017-05-10
JP6574203B2 (ja) 2019-09-11
AU2015254943B2 (en) 2019-04-04
CA2947130A1 (fr) 2015-11-05
AP2016009530A0 (en) 2016-10-31
CL2016002532A1 (es) 2017-04-21
AU2015254943A1 (en) 2016-10-27
NI201600163A (es) 2016-11-25
JP2019214597A (ja) 2019-12-19
US20190040055A1 (en) 2019-02-07
MX2016014143A (es) 2017-02-15
GT201600232A (es) 2019-10-10
CA2947130C (fr) 2018-10-02
US20180148441A1 (en) 2018-05-31
SV2016005310A (es) 2017-08-29
US10676471B2 (en) 2020-06-09
DOP2016000293A (es) 2016-12-30
EP3137460A1 (fr) 2017-03-08
KR20160149256A (ko) 2016-12-27
EA201650003A1 (ru) 2017-03-31
PE20161436A1 (es) 2017-01-08
NZ725496A (en) 2019-11-29
US10125130B2 (en) 2018-11-13
CN106232598B (zh) 2020-03-13
BR112016024513A2 (pt) 2017-08-15
TN2016000459A1 (en) 2018-04-04
DK3137460T3 (da) 2019-12-16
CN106232598A (zh) 2016-12-14
PL3137460T3 (pl) 2020-04-30
SG11201608634RA (en) 2016-11-29
CR20160497A (es) 2016-12-20

Similar Documents

Publication Publication Date Title
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA45920B1 (fr) Inhibiteurs de pyridopyrimidinone cdk2/4/6
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA47079A (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
MA39995B1 (fr) Composés destinés à traiter l'amyotrophie spinale
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA39777A (fr) Composes organiques de la famille des monobactams pour le traitement d'infections bactériennes
MA38175B1 (fr) Lactames fusionnés à un aryle et hétéroaryle
MA45222A (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA39043A1 (fr) Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA39926B1 (fr) Dérivés de dihétérocycle liés à cycloalkyle
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA37886A1 (fr) Nouvelles pyridinones bicycliques
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA54386B1 (fr) Modulateurs de trex1
MA47301B1 (fr) Inhibiteurs sélectifs de jak1
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
SV2011003839A (es) Agentes antifungicos
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA38009B1 (fr) Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer